Cure My Disease

Don't miss your cure!

 Log in / Sign up

HPV-Positive pelvic cancer: study probes hidden toll on sex life

NCT ID NCT07523152

Knowledge-focused Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 42 women with HPV-positive pelvic cancer (cervix, vagina, vulva, or anus) to understand how radiotherapy, with or without surgery, affects their sexual quality of life. Participants complete questionnaires about sexual function and emotional distress over time. The goal is to better describe these effects and guide future support strategies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women aged 18 or over. 2. Sexually active patients, i.e. those who have been sexually active in the year prior to their cancer diagnosis. 3. Patients being treated at the Montpellier Cancer Institute (ICM). 4. Patient with pelvic squamous cell carcinoma (cervix, vagina, vulva or anus) and human papillomavirus (HPV+) infection 5. Patient aware of her HPV status and how it is transmitted. 6. Indicated for external radiotherapy 7. Patient who has not received any oncological treatment prior to inclusion. 8. Patient who has given verbal consent. Exclusion Criteria: 1. Patients receiving radiotherapy treatment outside the Montpellier Cancer Institute (ICM). 2. Patients who are unwilling or unable to complete the study questionnaires. 3. Patients under guardianship, curatorship or court protection, 4. Patients for whom regular follow-up is impossible for psychological reasons, 5. Patients who do not speak French.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal carcinoma anus neoplasm cervical cancer cloacogenic carcinoma Pelvic Neoplasms uterine cancer vaginal cancer vulva cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anal cancer Pelvic cancer Vaginal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.